Fibrocell Science

Fibrocell Science, Inc., is an autologous cell therapy company focused on the development of innovative products for aesthetic, medical and scientific applications. The fibroblast cell plays a key role in the production of collagen and growth factors which support the skin and other soft tissues; therefore, these cells could play a key role in treating many medical conditions. They have a robust pipeline and clinical programs based on the autologous fibroblast cell. They believe their aesthetic indication is a beachhead for higher value indications.  They have a strong base of knowledge and expertise in cell based product development, manufacturing and seeking regulatory approvals. Their focus is to enter clinical programs to treat medical conditions that have an unmet need, helping patients and creating more value per cell.

Castle Creek Pharmaceutical Holdings announced it will acquire Fibrocell Science, Inc., a cell and gene therapy company in a $3 per share cash.

Fibrocell Spikes 60% After Receiving Cash Bid From Castle Creek Pharma

- Total consideration of $63.3 million, including repayment of debt and other financial instruments -

Castle Creek Pharmaceutical Holdings to Acquire Fibrocell

Fibrocell's (FCSC) gene therapy for a genetic skin disorder gets Regenerative Medicine Advanced Therapy designation, which expedites development process.

Fibrocell Up on FDA Designation for Gene Therapy Candidate

Is  (FCSC) Outperforming Other Medical Stocks This Year?

Is Fibrocell Science (FCSC) Stock Outpacing Its Medical Peers This Year?

Fibrocell Science's (FCSC) CEO John Maslowski on Q1 2019 Results - Earnings Call Transcript

Fibrocell (FCSC) misses estimates for earnings and sales in the first quarter of 2019.

Fibrocell (FCSC) Miss Estimates for Earnings & Revenues in Q1

Is Fibrocell Science (FCSC) Outperforming Other Medical Stocks This Year?

Fibrocell Science (FCSC) closed the most recent trading day at $2.30, making no change from the previous trading session.

Fibrocell Science (FCSC) Flat As Market Gains: What You Should Know

For Fibrocell's (FCSC) Q1, investors will eye the company's progress with its gene therapy candidate, FCX-007, currently being developed for treating recessive dystrophic epidermolysis bullosa.

Fibrocell (FCSC) Q1 Earnings: What's in Store for the Stock?

Is Fibrocell Science Outpacing Its Medical Peers?

Fibrocell established a partnership with Castle Creek Pharmaceuticals to advance the gene therapy product FCX-007 to treat patients with recessive dystrophic epidermolysis bullosa.

Fibrocell's Latest Partnership Provides A Leg Up For Gene Therapy Products

Fibrocell Science Inc (NASDAQ: FCSC) is one of Monday's biggest gainers

Fibrocell Strikes Funding Deal For Gene Therapy Candidate

Fibrocell Science, Inc. (FCSC) CEO John Maslowski on Q4 2018 Results - Earnings Call Transcript

News for Fibrocell Science Stock (FCSC)